Your browser is no longer supported. Please, upgrade your browser.
Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own35.45% Shs Outstand26.00M Perf Week1.92%
Market Cap68.90M Forward P/E- EPS next Y-1.33 Insider Trans0.00% Shs Float16.42M Perf Month3.92%
Income-28.90M PEG- EPS next Q-0.28 Inst Own28.40% Short Float4.73% Perf Quarter-15.87%
Sales- P/S- EPS this Y10.50% Inst Trans- Short Ratio3.88 Perf Half Y-45.92%
Book/sh0.69 P/B3.84 EPS next Y-98.50% ROA-75.40% Target Price22.50 Perf Year-33.75%
Cash/sh1.31 P/C2.03 EPS next 5Y- ROE-135.30% 52W Range2.05 - 6.45 Perf YTD-52.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.26% Beta-
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin- 52W Low43.90% ATR0.17
Employees25 Current Ratio2.90 Sales Q/Q- Oper. Margin- RSI (14)70.99 Volatility8.13% 8.08%
OptionableYes Debt/Eq0.60 EPS Q/Q19.90% Profit Margin- Rel Volume3.79 Prev Close2.65
ShortableYes LT Debt/Eq0.40 EarningsMar 07 BMO Payout- Avg Volume200.46K Price2.95
Recom1.00 SMA2019.68% SMA5014.08% SMA200-31.11% Volume656,474 Change11.32%
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Apr-26-18 07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire +11.32%
Apr-25-18 07:30AM  Wired News Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation ACCESSWIRE
Apr-24-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Apr-23-18 07:00AM  Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation GlobeNewswire
Apr-19-18 08:18PM  Should You Be Concerned About Axsome Therapeutics Incs (NASDAQ:AXSM) Investors? Simply Wall St.
07:00AM  Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer GlobeNewswire
Apr-11-18 07:00AM  Axsome Therapeutics to Participate in the Leerink Partners 2018 CNS Day GlobeNewswire
Mar-27-18 07:00AM  Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Mar-26-18 07:00AM  Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-19-18 07:00AM  Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-12-18 07:00AM  Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics GlobeNewswire
Mar-07-18 07:20AM  Axsome reports 4Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
06:00AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 07:00AM  Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 GlobeNewswire
Feb-26-18 08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
07:00AM  Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan GlobeNewswire
Feb-14-18 07:29PM  Is Axsome Therapeutics Incs (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Feb-05-18 07:00AM  Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference GlobeNewswire
Jan-10-18 09:17AM  Heres Whats Moving Axsome Therapeutics and Pain Therapeutics Market Exclusive
08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-09-18 07:00AM  Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial GlobeNewswire -36.04%
Dec-19-17 07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire
Dec-14-17 07:00AM  Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation GlobeNewswire
Dec-06-17 07:00AM  Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering GlobeNewswire
Dec-01-17 07:00AM  Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -6.64%
Nov-28-17 07:00AM  Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine GlobeNewswire
Nov-08-17 09:59AM  Axsome reports 3Q loss Associated Press -5.15%
07:00AM  Axsome Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Sep-18-17 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-07-17 07:00AM  Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017 GlobeNewswire
Aug-09-17 10:25PM  Axsome reports 2Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-25-17 07:00AM  Axsome Therapeutics Announces AXS-06 (MoSEIC Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial GlobeNewswire
Jul-17-17 07:00AM  Axsome Therapeutics Initiates Phase 2/3 Trial of AXS-05 for Alzheimers Disease Agitation GlobeNewswire
Jul-06-17 07:00AM  Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer GlobeNewswire
Jun-22-17 04:40AM  Will Axsome Therapeutics (AXSM) Continue to Surge Higher? Zacks
Jun-19-17 07:00AM  Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors GlobeNewswire +12.20%
May-09-17 09:55AM  Axsome reports 1Q loss Associated Press
08:15AM  Blog Coverage: Axsome Received Fast Track Designation for its Treatment of Agitation in Patients with Alzheimer's Disease Accesswire
07:00AM  Axsome Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-08-17 07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimers Disease Agitation GlobeNewswire +7.69%
Mar-31-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.14%
Mar-30-17 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-29-17 07:00AM  Axsome Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-23-17 07:00AM  Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-21-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -18.18%
09:20AM  Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock GlobeNewswire
Mar-20-17 04:06PM  Axsome Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-14-17 07:02AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-11-17 01:04PM  AXSOME THERAPEUTICS, INC. Financials
Mar-07-17 05:56PM  Axsome reports 4Q loss Associated Press -9.18%
05:17PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:56PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:35PM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Feb-27-17 07:00AM  Axsome Therapeutics to Present at the 29th Annual ROTH Conference GlobeNewswire +5.81%
Feb-14-17 05:24PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Treatment Resistant Depression GlobeNewswire
Feb-13-17 07:00AM  Axsome Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-10-17 07:01AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-07-17 07:00AM  Axsome Therapeutics to Present at the 2017 BIO CEO & Investor Conference GlobeNewswire
Jan-12-17 05:30PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-04-17 05:14PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2017 GlobeNewswire
Jan-03-17 07:00AM  Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Nov-14-16 06:01PM  Axsome reports 3Q loss
05:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:30PM  Axsome Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
04:10PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-10-16 04:32PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
07:00AM  Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank GlobeNewswire
Oct-05-16 12:38PM  Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
Oct-04-16 07:00AM  Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome GlobeNewswire
Oct-03-16 11:12AM  Axsome Therapeutics: Teaching Old Drugs New Tricks
Sep-29-16 09:18AM  5 Stocks Under $10 Poised for Big Breakouts
Sep-19-16 07:00AM  Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference GlobeNewswire
Sep-06-16 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-02-16 05:07PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
04:47PM  Axsome Therapeutics Announces Transition of Chief Medical Officer GlobeNewswire
Aug-10-16 06:03AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Aug-09-16 06:53PM  Axsome reports 2Q loss
05:30PM  Axsome Therapeutics Reports Second Quarter 2016 Financial Results GlobeNewswire
04:33PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:21PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report
04:12PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual Report
Jul-13-16 07:01AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jul-12-16 04:41PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review
Jul-05-16 07:00AM  Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference GlobeNewswire
Jun-27-16 07:00AM  Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes GlobeNewswire +7.75%
Jun-24-16 08:40AM  Axsome Therapeutics (AXSM) Catches Eye: Stock Jumps 6.6%
Jun-22-16 08:45AM  Can You Catch These 6 Stocks Under $10 on Their Way Up?
Jun-13-16 07:00AM  Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference GlobeNewswire -14.76%
Jun-10-16 04:08PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-11-16 05:20PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:48PM  Axsome reports 1Q loss
04:43PM  Axsome Therapeutics Reports First Quarter 2016 Financial Results GlobeNewswire
04:16PM  AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
May-05-16 06:05AM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-03-16 07:00AM  Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions GlobeNewswire -5.20%
Apr-21-16 04:42PM  AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.